邱海波，中山大學腫瘤防治中心（中山大學附屬腫瘤醫院）胃外科副主任醫師，碩士生導師。專注胃癌、胃腸間質瘤治療。
基本介紹
人物經歷,教育經歷,工作經歷,擅長領域,學術活動,社會兼職,獲得榮譽,學術文章,
人物經歷
教育經歷
2010.10－2012.09 哈佛大學醫學院聯合培養博士生
2009.09－2013.06 中山大學腫瘤防治中心腫瘤學博士
2006.09－2009.06 中山大學腫瘤防治中心腫瘤學碩士
2001.09－2006.06 廣州醫學院臨床醫學本科
工作經歷
2016.01-至今 中山大學腫瘤防治中心 胃外科 主治醫師
2013.08-2015.12 中山大學腫瘤防治中心 胃胰科 醫師
擅長領域
胃癌、胃腸間質瘤的綜合診治。
學術活動
翻譯NCCN胃腸間質瘤、胃癌指南，被NCCN指定為中文官方版。
社會兼職
翻譯NCCN胃腸間質瘤、胃癌指南，被NCCN指定為中文官方版。CSCO胃癌指南英文版翻譯小組組長。
中國臨床腫瘤學年會(CSCO)翻譯小組副組長,並長期擔任CSCO年會,BOA等大型會議的同聲傳譯、現場翻譯。
CSCO 胃腸間質瘤專家委員會委員
《NEJM醫學前言》中文版翻譯編輯
《腫瘤學雜誌》青年編委
廣東省中西醫結合胃腸外科專業委員會 委員
發起並成立中國胃腸間質瘤研究組（CN-GIST），任組長
成立國內第一家胃腸間質瘤患者俱樂部--有間俱樂部
獲得榮譽
2017 CSCO最具潛力腫瘤醫生獎
2017 GIST-TOUR 全國研究設計比賽 冠軍
2016 南中國胃腸間質瘤病例大賽 冠軍
2016 廣州胃腸間質瘤病例大賽 冠軍
2012 獲教育部第一三共獎學金
2012 中山大學優秀博士生
學術文章
Chen W#, Kuang Y#, Qiu HB#, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y1, Meng F, Fletcher JA, Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 Sep 15;77(18):5107-5117. IF 9.122
Zhang LY#, Wu JL#, Qiu HB#, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis. 2016 Mar;37(3):320-332. IF 5.105
Zhou ZG#, Chen JB#, Qiu HB#, Wang RJ, Chen JC, Xu L, Chen MS, Zhang YJ. Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget. 2016 May 10;7(19):27938-45. IF 5.168
Xuechao Liu#, Haibo Qiu#, Yuying Huang, Dazhi Xu, Wei Li, Yuanfang Li, Yingbo Chen, Zhiwei Zhou*, Xiaowei Sun*. Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients. Cancer Med. 2018 Feb; 7(2): 360–369. IF 3.362
Wei Zhuang#, Jing‐Dun Xie#, Shan Zhou, Zhi‐Wei Zhou, Yi Zhou, Xiao‐Wei Sun, Xiu‐Hong Yuan, Min Huang, Si Liu, Shuang Xin, Qi‐Biao Su, Hai‐Bo Qiu*, Xue‐Ding Wang*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med. 2018 Feb; 7(2): 317–324. IF 3.362
Seeruttun SR, Yuan S, Qiu HB#, Huang Y, Li Y, Liang Y, Guan Y, Zhan Y, Li W, Chen Y, Sun X, Xu D, Zhou Z. A comprehensive analysis comparing the eighth AJCC gastric cancer pathological classification to the seventh, sixth, and fifth editions. Cancer Med. 2017 Dec;6(12):2804-2813. IF 3.362
Liu X, Xu P, Qiu HB#, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Preoperative Nutritional Deficiency Is a Useful Predictor of Postoperative Outcome in Patients Undergoing Curative Resection for Gastric Cancer. Transl Oncol. 2016 Dec;9(6):482-488. IF 3.025
Liu X, Xu P, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther. 2016 Feb 26;9:949-58. IF 2.612
Hai-Bo Qiu#, Zhong-Guo Zhou#, Xing-Yu Feng#, Xue-Chao Liu, Jing Guo, Ming-Zhe Ma, Ying-Bo Chen, Xiao-Wei Sun*, Zhi-Wei Zhou*. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy. Medicine (Baltimore). 2018 Jan;97(2):e9097. IF 1.803
Qiu HB#, Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW, Wang XD. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2017 Aug 1. doi: 10.1038/tpj.2017.40. IF 3.815
Liu X, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Prognostic role of tumor necrosis in patients undergoing curative resection for gastric gastrointestinal stromal tumor: a multicenter analysis of 740 cases in China. Cancer Med. 2017 Dec;6(12):2796-2803. IF 3.362
Liu X#, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Ki-67 labeling index may be a promising indicator to identify "very high risk" gastrointestinal stromal tumor (GIST): a multicenter retrospective study of 1022 patients. Hum Pathol. 2017 Sep 26. pii: S0046-8177(17)30345-3. IF 3.014
Liu X#, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer. J Cancer. 2016 Oct 25;7(14):2148-2156. IF 2.916
Zhuang W#, Qiu HB#, Chen XM, Yuan XH, Yang LF, Sun XW, Zhou XJ, Huang M, Wang XD, Zhou ZW. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. Biomed Chromatogr. 2017 Dec;31(12). IF 1.601
Liu X, Qiu HB#, Kong P, Zhou Z, Sun X. Gastric cancer, nutritional status, and outcome. Onco Targets Ther. 2017 Apr 12; 10: 2107 - 2114. IF1.653
Qiu HB#, Zhang LY#, Ren C. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating wnt/β-catenin signaling. PLoS One. 2013;8(3):e56959. IF 2.806
Qiu HB#, Chen G, Keshari RP et.al. The extramural metastasis might be categorized in lymph node staging. BMC Cancer. 2011 Sep 26;11(1):414 IF 3.288
Qiu HB#, Zhang LY#, Li YF et al. Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer. Ann Surg Oncol. 2011 Jun;18(6):1568-74. IF 4.041
Qiu HB#, Zhang LY#, Zeng ZL, et.al. HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol. 2011 Feb 14;17(6):804-8. IF 3.365
Qiu HB#, Zhang LY#, Keshari RP et.al. Relationship between H.Pylori Infection and Clinicopathological Features and Prognosis of Gastric Cancer. BMC Cancer. BMC Cancer. 2010 Jul 17;10:374. IF 3.288
Qiu HB#, Wu XJ#, Zhou ZW, et.al. The Prognostic Significance of Peripheral T-lymphocyte Subsets and NK cells in Patients with Colorectal Cancer. Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1310-5. IF 1.012
邱海波，周志偉. NCCN胃癌臨床實踐指南2017年第五版更新要點解讀.中華胃腸外科雜誌.2018 Feb 21(2) 160-164
邱海波、張鵬、馮興宇、陳韜、孫曉衛、餘江、陳志京、李勇、陶凱雄、李國新、周志偉.中國四家醫療中心胃腸間質瘤診斷與治療的18年變遷. 中華胃腸外科雜誌.2016 Nov.19(11)1265-1270
邱海波、莊瑋、王雪丁、黃民、周志偉.胃腸間質瘤患者遺傳因素與伊馬替尼藥動學個體差異的相關性研究.中華胃腸外科雜誌2017 Sept.20(9)1031-1034
邱海波、孫曉衛、周志偉.胃腸間質瘤輔助治療研究新進展.中華胃腸外科雜誌.2017 Sept.20(9)961-965
邱海波、陳功、周志偉.胃腸間質瘤研究進展.中國普通外科雜.2017 Apr.26(4)1-6
邱海波、周志偉. 大數據時代胃腸間質瘤研究的使命. 中國普外基礎與臨床雜誌. 2017 Feb 24(2) 1-5
邱海波, 伍小軍，周志偉，等. 結直腸癌患者外周血T淋巴細胞亞群和NK細胞數目的變化及其臨床意義. 廣東醫學. Mar.2009,Vol.30,No.3,64-66
邱海波, 楊煒青，林澤英，等. 卡維地洛對異丙腎上腺素誘導小鼠心肌缺血的保護作用. 廣東醫學. 2009,July, supplement(1)
論文摘要
Haibo Qiu, Zhongguo Zhou, Xingyu Feng, Xiaowei Sun, Yingbo Chen, Yuanxiang Guan, Dazhi Xu, Yuanfang Li, Wei Li, Youqing Zhan, Rui-hua Xu, Zhiwei Zhou. Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy. Journal of Clinical Oncology 34, no. 15_suppl IF 24.008
Haibo Qiu, Wei Zhuang, Ting Wu, Min Huang, Zhiwei Zhou, Xueding Wang. Next generation sequencing (NGS) in wild type GISTs. Journal of Clinical Oncology 35, no. 15_suppl IF 24.008
